Silver Book Fact

Use of pneumonia vaccine in children reduced rates in adults age 65+

Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4; invasive pneumococcal disease rates in unvaccinated individuals age 65 and older fell by 18%.

Whitney, Cynthia G., Monica M. Farley, James Hadler, Lee H. Harrison, Nancy M. Bennett, et al.; for the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in Invasive Pneumococcal Disease After the Introduction of Protein-Polysaccharide Conjugate Vaccine. N Engl J Med. 2003; 348(18): 1737-46. http://www.nejm.org/doi/full/10.1056/NEJMoa022823

Reference

Title
Decline in Invasive Pneumococcal Disease After the Introduction of Protein-Polysaccharide Conjugate Vaccine
Publication
N Engl J Med
Publication Date
2003
Authors
Whitney, Cynthia G., Monica M. Farley, James Hadler, Lee H. Harrison, Nancy M. Bennett, et al.; for the Active Bacterial Core Surveillance of the Emerging Infections Program Network
Volume & Issue
Volume 348, Issue 18
Pages
1737-46
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • ~One-third of shingles death preventable with vaccine
    Approximately one-third of shingles deaths may be preventable through vaccination.  
  • Potential value of pneumonia vaccine
    Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4…  
  • Pertussis vaccination reduced global cases
    Vaccination helped reduce global pertussis (whooping cough) cases from 3 million per year to less 250,000.  
  • An antibiotic stewardship program saved $17 million over 8 years
    An antibiotic stewardship program saved a total of $17 million over 8 years, with antibiotic costs rising $1 million in the first year after discontinuation.  
  • Vaccines in development 2013
    137 vaccines are currently in development in the U.S. for infectious diseases.